- Home
- QXO vs PEN Comparison
QXO vs PEN Comparison
Compare QXO & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QXO | PEN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 10.9B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | QXO | PEN |
|---|---|---|
| Price | $21.39 | $313.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $33.45 | ★ $311.25 |
| AVG Volume (30 Days) | ★ 6.7M | 496.6K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 367.34 |
| EPS | N/A | ★ 4.14 |
| Revenue | ★ $4,662,873,000.00 | $1,333,798,000.00 |
| Revenue This Year | $12,120.21 | $16.77 |
| Revenue Next Year | $61.96 | $14.12 |
| P/E Ratio | ★ N/A | $75.22 |
| Revenue Growth | ★ 8107.98 | 14.61 |
| 52 Week Low | $11.85 | $221.26 |
| 52 Week High | $24.69 | $314.74 |
Technical Indicators
Market Signals| Indicator | QXO | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 68.40 |
| Support Level | $20.71 | $286.75 |
| Resistance Level | $21.41 | $303.00 |
| Average True Range (ATR) | 0.82 | 8.69 |
| MACD | 0.39 | 0.87 |
| Stochastic Oscillator | 83.15 | 95.39 |
Price Performance
Historical ComparisonAbout QXO QXO Inc. Common Stock
QXO Inc is a building products distribution company engaged in the distribution of roofing, waterproofing and complementary building products in North America. It offers a full suite of business applications, including ERP, warehouse management, accounting, CRM, and business intelligence solutions.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.